Imperial College London to present HBV data on CN Bio immune-competent liver model at AASLD The Liver Meeting

New advances in the pre-clinical evaluation of Hepatitis B therapies

Welwyn Garden City, UK, 2 Nov 2015: CN Bio Innovations Ltd, an expert in developing human organ chip platforms to test and develop therapeutics for serious diseases, has announced that new data from its research collaboration with Imperial College London, where the team are analysing a novel human, full-viral-lifecycle model of Hepatitis B, will be presented in the late-breaking poster session at The Liver Meeting® 2015, San Francisco USA (13-17 November, 2015).

Dr Marcus Dorner (Imperial College London), Lead Principle Investigator for the study, and Dr David Hughes, CN Bio’s Chief Technical Officer, will be available during the session which takes place on November the 16th from 12:30 – 2:00 pm to discuss the poster presentation entitled, “Microfluidic liver cultures as preclinical tool for the study of hepatitis B and C virus as well as malaria”.

filed under: Business